Bulte JP, et al. - Authors attempted to investigate if core needle biopsy (CNB) specimens processed with an accelerated processing method with short fixation time could be used to determine accurately the human epidermal growth factor receptor 2 (HER2) status of breast cancer. Using standard clinical testing methods, HER2 status could be determined reliably on CNB specimens with accelerated processing time. Using this accelerated technology the minimum 6 h of formalin fixation, which current guidelines regarded as necessary, could be decreased safely. This permitted for a complete and expedited histology-based diagnosis of breast lesions in the setting of a one-stop-shop, same-day breast clinic.